New target for acute myeloid leukaemia discovered
Researchers have identified a key weakness in acute myeloid leukaemia (AML), offering a promising new strategy to delay the progression of this aggressive blood cancer.
The discovery focuses on disrupting the function of the nucleosome-remodelling factor (NURF) complex, which cancer cells, including leukaemia cells, rely on to maintain their abnormal growth.
The research, led by scientists at The Institute of Cancer Research, London, revealed that targeting the NURF complex, particularly by inhibiting a specific cancer-driving protein within the complex – BPTF – could provide a new approach to treating AML.
AML’s complexity makes it a challenging cancer to treat due to its diverse genetic mutations, rapid progression and resistance to existing therapies such as chemotherapy and bone marrow transplants, which often come with severe side effects.
Experiments in cell cultures, conducted by the research team, show that the disruption of BPTF and the associated NURF complex can impair the leukaemia’s ability to thrive. By clarifying the essential role of BPTF in leukaemia survival, the team hopes to identify and present safer treatment options for patients.
Approach could apply to other cancers
The study shows how the deregulation of NURF can affect the 3D chromatin structure in the cell, including the higher-order chromatin organisation surrounding the MYC gene, altering MYC transcription. It is possible that this mechanism is also relevant for other cancer types.
Dr Alex Radzisheuskaya, Leader of the Chromatin Biology Group at the ICR and co-corresponding author, said: “We hope this research provides hope to people affected by AML by revealing a potential new target for cancer treatment that doesn’t rely on conventional approaches. Instead, therapies could now focus on interfering with the NURF complex’s ability to organise the cancer genome, effectively hindering its growth at a fundamental level.
“Our early findings suggest that such an approach could effectively destroy cancer while being less harmful to normal cells, which is crucial in reducing side effects for patients.”
The research, published in The EMBO Journal, was funded by several organisations, including the European Union’s Horizon 2020 research and innovation programme under Marie Sklodowska-Curie grant agreements, the Kirsten and Freddy Johansen Foundation, the Neye Foundation and the Brain Tumour Charity.
Diana Spencer, Senior Digital Content Editor, DDW
